Armstrong Advisory Group’s Axsome Therapeutics AXSM Stock Holding History

Armstrong Advisory Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$78.2K	Buy	424 +1	+0.2%	+$218	﹤0.01%	371
2026 Q2	$104K	Hold	423	–	–	0.01%	343
2026 Q1	$71.5K	Hold	423	–	–	﹤0.01%	359
2025 Q4	$77.3K	Hold	423	–	–	0.01%	341
2025 Q3	$51.4K	Hold	423	–	–	﹤0.01%	393
2025 Q2	$44.2K	Hold	423	–	–	﹤0.01%	400
2025 Q1	$35.8K	Hold	423	–	–	﹤0.01%	419
2024 Q4	$35.8K	Hold	423	–	–	﹤0.01%	419
2024 Q3	$38K	Hold	423	–	–	﹤0.01%	404
2024 Q2	$34.1K	Hold	423	–	–	﹤0.01%	406
2024 Q1	$33.7K	Hold	423	–	–	﹤0.01%	398
2023 Q4	$33.7K	Hold	423	–	–	﹤0.01%	398
2023 Q3	$29.6K	Hold	423	–	–	﹤0.01%	414
2023 Q2	$30.4K	Hold	423	–	–	﹤0.01%	414
2023 Q1	$26.1K	Hold	423	–	–	﹤0.01%	430
2022 Q4	$32.6K	Buy	+423	New	+$25.3K	﹤0.01%	404

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Cannon Advisors Charlotte, North Carolina $172M AUM 16.61% 1-Year Est. Return

Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return

Armstrong Advisory Group's AXSM Position: Q3 2026 in Review

Armstrong Advisory Group increased its Axsome Therapeutics (AXSM) stake by 0.24% in Q3 2026, buying an estimated $218 and bringing the position to 424 shares worth $78.2K. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Armstrong Advisory Group first reported a position in AXSM in Q4 2022 and has held it in 16 quarters since. The position peaked at $104K in Q2 2026. 42 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Armstrong Advisory Group held 424 shares of Axsome Therapeutics worth $78.2K as of Q3 2026.
Armstrong Advisory Group bought 1 Axsome Therapeutics share in Q3 2026, an estimated $218.
Axsome Therapeutics made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #371 holding.
Armstrong Advisory Group first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 16 quarters since.
Armstrong Advisory Group's Axsome Therapeutics position peaked at $104K in Q2 2026.
42 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.